KRAS and Myelodysplasia: The presence of poor-risk cytogenetic abnormalities, the presence of other mutations in myeloid genes, and the presence of mutations in myelodysplasia-related genes and/or mutations in NRAS/KRAS did not seem to have a significant impact on the EFS and OS.